This inventor holds 2 USPTO granted patents and 1 published patent application and 3 EPO patents. Top assignee: Ruprecht-Karls-Universitat Heidelberg. Active years: 2018-2022.
Company Filing History:
Years Active: 2018-2022
Title: Lorenz Lehmann: Innovator in Cardiovascular Therapeutics
Introduction
Lorenz Lehmann is a notable inventor based in Heidelberg, Germany. He has made significant contributions to the field of cardiovascular medicine through his innovative research and patented inventions. With a total of 2 patents, Lehmann's work focuses on therapeutic approaches for treating heart failure.
Latest Patents
Lehmann's latest patents include groundbreaking inventions related to Abhydrolase containing domain 5 (ABHD5) and N-terminal fragments of HDAC4 (HDAC4-NT). These inventions aim to provide therapeutic solutions for the treatment and prevention of cardiovascular diseases. The patents detail vectors for cardiomyocyte-specific expression of these peptides and a test system comprising ABHD5 for identifying novel compounds useful in treating heart failure.
Career Highlights
Throughout his career, Lorenz Lehmann has been associated with prestigious institutions such as Ruprecht-Karls-University Heidelberg and Ruprecht-Karls-Universität Heidelberg. His work has been instrumental in advancing the understanding and treatment of cardiovascular conditions.
Collaborations
Lehmann has collaborated with esteemed colleagues, including Johannes Backs and Zegeye Jebessa. These partnerships have further enriched his research and contributed to the development of innovative therapeutic strategies.
Conclusion
Lorenz Lehmann's contributions to cardiovascular therapeutics through his patents and collaborations highlight his role as a leading inventor in the field. His work continues to pave the way for advancements in the treatment of heart failure.